Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Debt (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-Current Debt for 5 consecutive years, with $100.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 6.82% to $100.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $100.9 million, a 6.82% decrease, with the full-year FY2025 number at $100.9 million, down 6.82% from a year prior.
  • Non-Current Debt was $100.9 million for Q4 2025 at Rhythm Pharmaceuticals, down from $103.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $108.3 million in Q4 2024 to a low of $100.9 million in Q4 2025.
  • A 3-year average of $105.4 million and a median of $106.1 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: grew 2.0% in 2024, then dropped 6.82% in 2025.
  • Rhythm Pharmaceuticals' Non-Current Debt stood at $106.1 million in 2023, then grew by 2.0% to $108.3 million in 2024, then dropped by 6.82% to $100.9 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Non-Current Debt are $100.9 million (Q4 2025), $103.4 million (Q3 2025), and $106.0 million (Q2 2025).